Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of an investigational, once-a-day pill called brenso­catib as a therapy for the chronic lung condition. It could soon become the first-ever FDA-approved treatment for bronchiectasis.

Baycrest is thrilled to announce the appointment of Dr. Lei Wang as the inaugural Vice-President of Scientific Affairs with Baycrest Academy for Research and Education (BARE).

Following an international search, Dr. Wang will join Baycrest on August 19, 2025 from The Ohio State University’s College of Medicine, where he is a tenured Full Professor in the Departments of Psychiatry and Behavioural Health, and Neuroscience.

Finding has implications for treating common neuropsychiatric disorders